Advertisement
Screener

Pacific Biosciences of California, Inc. (PACB) Business Acquisition, Pro Forma Revenue

2.1 / 5 stars · 30/72 Roast Me

Pacific Biosciences of California, Inc. Business Acquisition, Pro Forma Revenue

Pacific Biosciences of California, Inc. (PACB) reported Business Acquisition, Pro Forma Revenue of $34.89 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2022-11-08.

Discontinued › Income Statement › Other Income

us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2022-11-08

  • Pacific Biosciences of California, Inc. business acquisition, pro forma revenue for the quarter ending 2021-09-30 was $34.89M, a 82.83% increase year-over-year.
  • Pacific Biosciences of California, Inc. business acquisition, pro forma revenue for the quarter ending 2020-09-30 was $19.08M.
Period endBusiness Acquisition, Pro Forma Revenue 3 monthBusiness Acquisition, Pro Forma Revenue 9 month
2021-09-30$34.89M
10-Q · filed 2022-11-08
$94.49M
10-Q · filed 2021-11-05
2020-09-30$19.08M
10-Q · filed 2021-11-05
$51.76M
10-Q · filed 2021-11-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
908 Devices Inc. (MASS)United States$0.476B-9.53
EyePoint, Inc. (EYPT)United States$0.314B-3.96
Cytek Biosciences, Inc. (CTKB)United States$0.744B-7.15
Quanterix Corp (QTRX)United States$0.150B-1.65
Nautilus Biotechnology, Inc. (NAUT)United States$0.129B-4.16
Seer, Inc. (SEER)United States$0.104B-1.34
Precipio, Inc. (PRPO)United States$0.043B-36.70
HARVARD BIOSCIENCE INC (HBIO)United States$0.037B-2.70
Bionano Genomics, Inc. (BNGO)United States$0.020B-0.42
ASTROTECH Corp (ASTC)United States$0.013B